hyperaldosteronism
HYPERALDOSTERONISM
Hyperaldosteronism is a group of disorders in which aldosterone production is inappropriately high, relatively autonomous & non-suppressible by sodium loading.
Signs & symptoms are nonspecific.
Symptoms are caused by hypertension (eg headache), hypokalemia (eg polyuria, nocturia, muscle cramps & weakness, tetany, paralysis, etc) & metabolic alkalosis.

Principles of Therapy

  • Patients with bilateral adrenal hyperplasia or those unsuitable for surgery is recommended to be treated medically by mineralocorticoid receptor antagonists
    • They appear to be effective in blood pressure control and protection for blood pressure-independent target organ

Pharmacotherapy

Spironolactone
  • First-line agent for the medical treatment of hyperaldosteronism
  • Mineralocorticoid receptor antagonist that acts on the distal portion of the renal tubule as a competitive antagonist of aldosterone and it also increases sodium and water excretion and reduces potassium excretion
  • An androgen receptor antagonist and progesterone agonist
  • Dose-related gynecomastia was observed
  • A small dose of thiazide diuretic, Triamterine, or Amiloride may be given to avoid the side effects of high dose Spironolactone
Eplerenone
  • Alternative to Spironolactone
  • Selective mineralocorticoid antagonist that has no anti-androgen and progesterone agonist effects
  • It should be given twice daily due to its shorter half-life
Amiloride
  • An epithelial sodium channel antagonist that can ameliorate blood pressure and hypokalemia
  • Less efficacious than Spironolactone but may be useful
  • It has no sex steroid-related side effects but no beneficial effects on endothelial function
Angiotensin-converting enzyme (ACE) inhibitor
  • Can be added if hypertension persists
  • For patients with angiotensin II sensitive adenoma or hyperplasia
  • Efficacy in the low plasma renin state may in part reflect the role of even low concentrations of angiotensin II as an aldosterone secretagogue in adrenal hyperplasia
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
06 Oct 2018
Supplementation with resistant starch for 12 weeks decreases the inflammatory marker tumour necrosis factor [TNF]-α and heart rate but does not significantly improve glycaemic control and other cardiovascular disease risk factors in prediabetic adults, suggests a study.
12 Nov 2019
Use of the feminizing hormone therapy medroxyprogesterone acetate (MPA) results in minimal side effects, unchanged oestradiol levels and a decline in testosterone in a cohort of transwomen, a study has found.
29 Sep 2019
The duration and degree of overweight in adulthood appear to have lasting influence on breast and colorectal cancer survival, a study has found.
22 Jul 2019
The risk of diabetes mellitus is higher among postmenopausal women who develop primary breast cancer, reports a new study.